SelinidinCAS# 19427-82-8 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 19427-82-8 | SDF | Download SDF |
PubChem ID | 668079 | Appearance | Powder |
Formula | C19H20O5 | M.Wt | 328.4 |
Type of Compound | Coumarins | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [(9S)-8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-h]chromen-9-yl] (Z)-2-methylbut-2-enoate | ||
SMILES | CC=C(C)C(=O)OC1CC2=C(C=CC3=C2OC(=O)C=C3)OC1(C)C | ||
Standard InChIKey | RRHCDWLSHIIIIT-GHAIFCDISA-N | ||
Standard InChI | InChI=1S/C19H20O5/c1-5-11(2)18(21)22-15-10-13-14(24-19(15,3)4)8-6-12-7-9-16(20)23-17(12)13/h5-9,15H,10H2,1-4H3/b11-5-/t15-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Selinidin decreases phosphorylation of phospholipase C-gamma1, p38 mitogen-activated protein kinase, and IkappaB-alpha upon FcepsilonRI stimulation. |
Targets | TNF-α | p38MAPK | IkB | IKK |
Selinidin Dilution Calculator
Selinidin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0451 mL | 15.2253 mL | 30.4507 mL | 60.9013 mL | 76.1267 mL |
5 mM | 0.609 mL | 3.0451 mL | 6.0901 mL | 12.1803 mL | 15.2253 mL |
10 mM | 0.3045 mL | 1.5225 mL | 3.0451 mL | 6.0901 mL | 7.6127 mL |
50 mM | 0.0609 mL | 0.3045 mL | 0.609 mL | 1.218 mL | 1.5225 mL |
100 mM | 0.0305 mL | 0.1523 mL | 0.3045 mL | 0.609 mL | 0.7613 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- N-Acetyl-5,6-dehydrololine
Catalog No.:BCN2007
CAS No.:194205-01-1
- Isohyenanchin
Catalog No.:BCN1187
CAS No.:19417-00-6
- Isosaponarin
Catalog No.:BCN2279
CAS No.:19416-87-6
- Rivulobirin B
Catalog No.:BCN1186
CAS No.:194145-29-4
- Dihydrocapsaicin
Catalog No.:BCN1017
CAS No.:19408-84-5
- 3-Amino-4-methylbenzamide
Catalog No.:BCC8614
CAS No.:19406-86-1
- 6,19-Dihydroxyurs-12-en-3-oxo-28-oic acid
Catalog No.:BCN1513
CAS No.:194027-11-7
- Cedrelopsin
Catalog No.:BCN7687
CAS No.:19397-28-5
- 10-O-Vanilloylaucubin
Catalog No.:BCN1185
CAS No.:193969-08-3
- Fmoc-β-HoPhe-OH
Catalog No.:BCC3241
CAS No.:193954-28-8
- Fmoc- ß-HoIle-OH
Catalog No.:BCC3237
CAS No.:193954-27-7
- Fmoc-ß-HoAla-OH
Catalog No.:BCC3225
CAS No.:193954-26-6
- Curcumenol
Catalog No.:BCN3522
CAS No.:19431-84-6
- Ac-D-Ala-OH
Catalog No.:BCC3196
CAS No.:19436-52-3
- Benzyl Caffeate
Catalog No.:BCC5100
CAS No.:107843-77-6
- CL-387785 (EKI-785)
Catalog No.:BCC6436
CAS No.:194423-06-8
- PD168393
Catalog No.:BCC1157
CAS No.:194423-15-9
- Taberpsychine
Catalog No.:BCN4047
CAS No.:19452-84-7
- 24-Norhopa-4(23),22(29)-diene-3β,6β-diol
Catalog No.:BCN1512
CAS No.:194613-74-6
- Rubrosterone
Catalog No.:BCN1511
CAS No.:19466-41-2
- GaTx2
Catalog No.:BCC6326
CAS No.:194665-85-5
- Melittoside
Catalog No.:BCN8413
CAS No.:19467-03-9
- Taxuspine X
Catalog No.:BCN6936
CAS No.:194782-02-0
- Dracoflavan B1
Catalog No.:BCN3589
CAS No.:194794-44-0
Selinidin suppresses IgE-mediated mast cell activation by inhibiting multiple steps of Fc epsilonRI signaling.[Pubmed:18310907]
Biol Pharm Bull. 2008 Mar;31(3):442-8.
IgE-mediated mast cell activation is critical for development of allergic inflammation. We have recently found that Selinidin, one of the coumarin derivatives isolated from Angelica keiskei, attenuates mast cell degranulation following engagement of the high-affinity receptor for IgE (Fc epsilonRI) with IgE and antigen. In the present study, we investigated the effects of Selinidin on intracellular signaling and mast cell activation employing bone marrow-derived mast cells. Here, we report that Selinidin attenuates the release of beta-hexosaminidase, synthesis of leukotriene C4, and production of tumor necrosis factor-alpha without affecting IgE-Fc epsilonRI binding. Furthermore, biochemical analyses of the Fc epsilonRI-mediated signaling pathway demonstrated that Selinidin decreases phosphorylation of phospholipase C-gamma1, p38 mitogen-activated protein kinase, and IkappaB-alpha upon FcepsilonRI stimulation. These results suggest that this compound suppresses IgE-mediated mast cell activation by inhibiting multiple steps of FcepsilonRI-dependent signaling pathways and would be beneficial for the prevention of allergic inflammation.